Tscan Therapeutics Long Term Debt

Tscan Therapeutics (TCRX) currently reports a long-term debt of $71M as of June 2026. That compares with $58M in the prior-year period — up 23.0% year over year. Use the charts on this page to explore Tscan Therapeutics's long-term debt history and peer comparisons.

Tscan Therapeutics's long-term debt increased from $58M to $71M — a 23.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tscan Therapeutics reported $71M in long-term debt as of June 2026. That compares with $58M in the prior-year period — up 23.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $71M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Tscan Therapeutics, and consider following TCRX for alerts when major investors trade the stock.

Tscan Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $71M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TCRX with unrelated industries.